Elaine Chow1,2, Ahmed Iqbal1,2, Emma Walkinshaw2,3, Fladia Phoenix4, Ian A Macdonald5, Robert F Storey1,3, Ramzi Ajjan4, Simon R Heller6,3. 1. Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, U.K. 2. Department of Oncology and Metabolism, University of Sheffield, Sheffield, U.K. 3. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, U.K. 4. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K. 5. School of Life Sciences, University of Nottingham, Nottingham, U.K. 6. Department of Oncology and Metabolism, University of Sheffield, Sheffield, U.K. s.heller@shef.ac.uk.
Abstract
OBJECTIVE: Hypoglycemia has been linked to persistent increases in cardiovascular (CV) mortality in type 2 diabetes after the event. Our aim was to examine acute and downstream effects of hypoglycemia on markers of thrombosis risk and inflammation in type 2 diabetes. RESEARCH DESIGN AND METHODS: Twelve individuals with type 2 diabetes with no history of CV disease and 11 age- and BMI-matched volunteers without diabetes underwent paired hyperinsulinemic-euglycemic (glucose 6 mmol/L for two 60-min periods) and hypoglycemic (glucose 2.5 mmol/L for two 60-min periods) clamps on separate occasions on day 0. Fibrin clot properties, platelet reactivity, and inflammatory markers were measured at baseline, end of and after recovery from the initial clamp, day 1, and day 7 using validated assays and electron microscopy. RESULTS: Euglycemic hyperinsulinemia reduced platelet reactivity, decreased fibrin clot density, and improved fibrinolytic efficiency in both groups. Platelet reactivity and aggregation increased during acute hypoglycemia in both groups, resolving at recovery. In type 2 diabetes, clot lysis times and clot maximum absorbance increased up to day 7 (P = 0.002 and 0.001 vs. euglycemia, respectively), but clots from control subjects without diabetes showed limited changes. Fibrin network density increased Δ 1.15 ± 0.28 fibers/μm2 at day 7 after the hypoglycemic clamp (P < 0.01 for glycemic arm), whereas fibrinogen and complement C3 increased after hypoglycemia up to day 7 in type 2 diabetes only. CONCLUSIONS: Antecedent hypoglycemia has acute and persistent prothrombotic effects, lasting at least 7 days, that were enhanced in individuals with type 2 diabetes. These findings identify mechanisms by which hypoglycemia might increase short- and medium-term risk of CV mortality.
OBJECTIVE:Hypoglycemia has been linked to persistent increases in cardiovascular (CV) mortality in type 2 diabetes after the event. Our aim was to examine acute and downstream effects of hypoglycemia on markers of thrombosis risk and inflammation in type 2 diabetes. RESEARCH DESIGN AND METHODS: Twelve individuals with type 2 diabetes with no history of CV disease and 11 age- and BMI-matched volunteers without diabetes underwent paired hyperinsulinemic-euglycemic (glucose 6 mmol/L for two 60-min periods) and hypoglycemic (glucose 2.5 mmol/L for two 60-min periods) clamps on separate occasions on day 0. Fibrin clot properties, platelet reactivity, and inflammatory markers were measured at baseline, end of and after recovery from the initial clamp, day 1, and day 7 using validated assays and electron microscopy. RESULTS: Euglycemic hyperinsulinemia reduced platelet reactivity, decreased fibrin clot density, and improved fibrinolytic efficiency in both groups. Platelet reactivity and aggregation increased during acute hypoglycemia in both groups, resolving at recovery. In type 2 diabetes, clot lysis times and clot maximum absorbance increased up to day 7 (P = 0.002 and 0.001 vs. euglycemia, respectively), but clots from control subjects without diabetes showed limited changes. Fibrin network density increased Δ 1.15 ± 0.28 fibers/μm2 at day 7 after the hypoglycemic clamp (P < 0.01 for glycemic arm), whereas fibrinogen and complement C3 increased after hypoglycemia up to day 7 in type 2 diabetes only. CONCLUSIONS: Antecedent hypoglycemia has acute and persistent prothrombotic effects, lasting at least 7 days, that were enhanced in individuals with type 2 diabetes. These findings identify mechanisms by which hypoglycemia might increase short- and medium-term risk of CV mortality.
Authors: Felix Aberer; Peter N Pferschy; Norbert J Tripolt; Caren Sourij; Anna M Obermayer; Florian Prüller; Eva Novak; Philipp Reitbauer; Harald Kojzar; Barbara Prietl; Selina Kofler; Martina Brunner; Eva Svehlikova; Tatjana Stojakovic; Hubert Scharnagl; Abderrahim Oulhaj; Faisal Aziz; Regina Riedl; Harald Sourij Journal: Diabetes Obes Metab Date: 2019-11-03 Impact factor: 6.577
Authors: James Ling; Emily W M Poon; Aimin Yang; Theresa Yeung; Kitman Loo; Risa Ozaki; Ronald C W Ma; Andrea O Y Luk; Alice P S Kong; Juliana C N Chan; Elaine Chow Journal: Diabetes Ther Date: 2021-03-18 Impact factor: 2.945
Authors: Xiaoling Li; Nina C Weber; Danny M Cohn; Markus W Hollmann; J Hans DeVries; Jeroen Hermanides; Benedikt Preckel Journal: J Clin Med Date: 2021-05-29 Impact factor: 4.241
Authors: Wael Sumaya; Lars Wallentin; Stefan K James; Agneta Siegbahn; Katja Gabrysch; Anders Himmelmann; Ramzi A Ajjan; Robert F Storey Journal: Thromb Haemost Date: 2020-01-23 Impact factor: 5.249